Zhitong Finance App News, Weilizhibo-B (09887.HK) announced that the first case of systemic lupus erythematosus (LBL-047—CN001) has successfully completed the administration of the first case of systemic lupus erythematosus (SLE), a novel bispecific fusion protein LBL-047 (known as DNTH212), a transmembrane activator and calciclophilin ligand interacting molecule (TACI) independently developed by the company. BDCA2 This is the first time LBL-047 has entered the population of patients with autoimmune diseases. The molecule acts simultaneously on two clinically proven pathogenesis pathways, innate immunity and adaptive immunity, and the LBL-047 has a complementary and differentiated dual-target design, which has been directly verified in patients for the first time.

Zhitong Finance App News, Weilizhibo-B (09887.HK) announced that the first case of systemic lupus erythematosus (LBL-047—CN001) has successfully completed the administration of the first case of systemic lupus erythematosus (SLE), a novel bispecific fusion protein LBL-047 (known as DNTH212), a transmembrane activator and calciclophilin ligand interacting molecule (TACI) independently developed by the company. BDCA2 This is the first time LBL-047 has entered the population of patients with autoimmune diseases. The molecule acts simultaneously on two clinically proven pathogenesis pathways, innate immunity and adaptive immunity, and the LBL-047 has a complementary and differentiated dual-target design, which has been directly verified in patients for the first time.